Cutaneous bacteria – cellular components

Cutaneous bacteria – cellular components is a broad therapeutic target category encompassing the structural and metabolic machinery of microorganisms residing on human skin, most notably Cutibacterium acnes and Staphylococcus aureus. These components, which include the bacterial cell wall, ribosomes, and essential enzymes like DNA gyrase, are the primary focus of topical and systemic antimicrobial therapies used to treat dermatological conditions such as acne vulgaris, impetigo, and atopic dermatitis. In these diseases, bacterial overgrowth or dysbiosis triggers inflammatory cascades and impairs the skin's barrier function. Drugs targeting these cellular components act by disrupting essential life processes, such as protein synthesis or nucleic acid assembly, thereby reducing the bacterial population and associated inflammation. However, the clinical management of these targets is increasingly challenged by the emergence of antibiotic resistance and the potential for adverse effects on the beneficial commensal flora that maintains skin homeostasis. Effective therapy requires balancing the reduction of pathogenic load with the preservation of the skin's natural microbial diversity.

Other names

Skin microbiota componentsDermal bacterial floraBacterial cell wall and ribosomes (cutaneous)Cutaneous microbiome targets

Antimicrobial agents targeting cutaneous bacteria work through diverse mechanisms, including the inhibition of protein synthesis by binding to the 30S or 50S ribosomal subunits, the inhibition of DNA replication via DNA gyrase and topoisomerase IV, the disruption of cell wall peptidoglycan synthesis, and the generation of reactive oxygen species that cause non-specific oxidative damage to bacterial membranes and proteins.